MiMedx wins FDA regenerative med status for AmnioFix

This article was originally published here

MiMedx (NSDQ:MDXG) won regenerative medicine advanced therapy status from the FDA for its injectable osteoarthritis drug, AmnioFix, the company announced this week.

The U.S. regulatory watchdog told MiMedx that the company provided sufficient preliminary evidence that AmnioFix could address unmet needs for patients with osteoarthritis of the knee.

Get the full story at our sister site, Drug Delivery Business News.

The post MiMedx wins FDA regenerative med status for AmnioFix appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply